-

09:35:17 PM

EBS Stock News

EBS - Emergent Biosolutions Inc

06/24/22 6:30 AM

NYSE : EBS

Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the company’s new

RHEA-AI

neutral

06/21/22 6:30 AM

NYSE : EBS

clinical trial

Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP)

RHEA-AI

neutral

06/02/22 8:20 AM

NYSE : EBS

conferences

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: Benchmark Healthcare House Call Virtual 1X1 Conference June 2, 2022 NYSE

RHEA-AI

neutral

05/16/22 6:32 AM

NYSE : EBS

acquisition

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threat Transaction to be funded with currently available funds; Expected to be accretive beginning with anticipated product

RHEA-AI

neutral

05/12/22 6:30 AM

NYSE : EBS

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT

Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL

RHEA-AI

neutral

04/28/22 4:05 PM

NYSE : EBS

earnings

Emergent BioSolutions Reports Financial Results For First Quarter 2022

Emergent BioSolutions Inc. (NYSE: EBS) today reported

RHEA-AI

neutral

04/08/22 6:30 AM

NYSE : EBS

earnings

Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the

RHEA-AI

neutral

03/23/22 4:05 PM

NYSE : EBS

Emergent BioSolutions Provides Corporate Governance Update

Emergent BioSolutions Inc.

RHEA-AI

very positive

03/14/22 4:05 PM

NYSE : EBS

conferences

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: KeyBanc Life Sciences & MedTech Investor Forum March 22, 2022 Company

RHEA-AI

neutral

03/11/22 6:34 AM

NYSE : EBS

clinical trial

Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning

Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatment

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

EBS Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.emergentbiosolutions.com
CeoRobert Kramer
Security nameEmergent Biosolutions Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2200
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address400 Professional Dr Ste 400
StateMaryland
CityGaithersburg
Zip20879-3457
CountryUS
Phone12406313200

About Emergent Biosolutions Inc

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent BioSolutions aims to build healthier and safer communities. The company aspires to deliver peace of mind to theis patients and customers so they can focus on what's most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030.